Last updated on September 2018

A Study of Atezolizumab Plus Cobimetinib and Vemurafenib Versus Placebo Plus Cobimetinib and Vemurafenib in Previously Untreated BRAFv600 Mutation-Positive Patients With Metastatic or Unresectable Locally Advanced Melanoma


Brief description of study

This is a Phase III, double-blinded, placebo-controlled, randomized, multicenter study designed to evaluate the efficacy, safety, and pharmacokinetics of atezolizumab + cobimetinib + vemurafenib compared with placebo + cobimetinib + vemurafenib in patients with previously untreated BRAFv600 mutation-positive metastatic or unresectable locally advanced melanoma.

Clinical Study Identifier: NCT02908672

Contact Investigators or Research Sites near you

Start Over

Reference Study ID Number: CO39262 ...

Centrum Onkologii Instytut Klinika Nowotworow Ukladowych i Uogolnionych
Krakow, Poland

Reference Study ID Number: CO39262 ...

Szpital Uniwersytecki w Krakowie, Oddzia Kliniczny Kliniki Onkologii
Krakow, Poland
0.76miles

Recruitment Status: Closed


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.